Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for treating cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for treating patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for treating pain; CTX001, which is in Phase I/II trial for treating beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc., as well as a research collaboration with Arbor Biotechnologies to discover DNA endonucleases for cystic fibrosis and four other diseases. It also has a collaboration with X-Chem, Inc. to develop DNA-encoded DEX libraries. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-341-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.05 billion
Profitability
Miscellaneous
Employees2,500
OptionableOptionable
Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions
What is Vertex Pharmaceuticals' stock symbol?
Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
How will Vertex Pharmaceuticals' stock buyback program work?
Vertex Pharmaceuticals declared that its board has authorized a share buyback plan on Thursday, February 1st 2018, which permits the company to buyback $500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to buy shares of its stock through open market purchases. Stock buyback plans are usually a sign that the company's leadership believes its stock is undervalued.
How were Vertex Pharmaceuticals' earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced its quarterly earnings results on Tuesday, February, 5th. The pharmaceutical company reported $1.30 EPS for the quarter, beating the consensus estimate of $1.06 by $0.24. The pharmaceutical company had revenue of $870.11 million for the quarter, compared to analyst estimates of $818.29 million. Vertex Pharmaceuticals had a return on equity of 24.15% and a net margin of 68.81%. The business's revenue was up 33.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.61 EPS. View Vertex Pharmaceuticals' Earnings History.
When is Vertex Pharmaceuticals' next earnings date?
What price target have analysts set for VRTX?
17 analysts have issued 12 month price targets for Vertex Pharmaceuticals' stock. Their predictions range from $165.71 to $234.00. On average, they expect Vertex Pharmaceuticals' share price to reach $204.6473 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.
What is the consensus analysts' recommendation for Vertex Pharmaceuticals?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.
What are Wall Street analysts saying about Vertex Pharmaceuticals stock?
Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Consistent increase in eligible patient population for Vertex’s CF drugs, Kalydeco & Orkambi, is driving sales growth. Vertex’s third CF medicine Symdeko was approved in the United States in February and has been a significant contributor to growth in 2018. Vertex’s CF pipeline is also accelerating rapidly. However, Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Meanwhile, since Symdeko’s launch, Orkambi revenues are being hurt by patient switch to Symdeko. Also, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. The company has a positive record of earnings surprises in the recent quarters and estimates have gone up ahead of Q4 earnings release." (1/26/2019)
- 2. Cantor Fitzgerald analysts commented, ". Reiterate overweight and $217 price target. This morning, Vertex announced that CFO Tom Graney has resigned effective immediately. He joined 2017, so his tenure was relatively short." (12/17/2018)
Has Vertex Pharmaceuticals been receiving favorable news coverage?
News headlines about VRTX stock have been trending somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Vertex Pharmaceuticals earned a media sentiment score of 1.4 on InfoTrie's scale. They also gave media coverage about the pharmaceutical company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are some of Vertex Pharmaceuticals' key competitors?
Some companies that are related to Vertex Pharmaceuticals include Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Shire (SHPG), Regeneron Pharmaceuticals (REGN), Allergan (AGN), Zoetis (ZTS) and Takeda Pharmaceutical (TKPYY).
Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the folowing people:
- Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)
- Dr. David M. Altshuler, Chief Scientific Officer & Exec. VP of Global Research (Age 54)
- Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)
- Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)
- Mr. Thomas Graney, Exec. (Age 54)
Who are Vertex Pharmaceuticals' major shareholders?
Vertex Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.67%), Jennison Associates LLC (2.72%), Oregon Public Employees Retirement Fund (1.80%), Geode Capital Management LLC (1.20%), Northern Trust Corp (1.13%) and Bank of New York Mellon Corp (0.86%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.
Which major investors are selling Vertex Pharmaceuticals stock?
VRTX stock was sold by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Prudential Financial Inc., Orbimed Advisors LLC, State of Tennessee Treasury Department, BlackRock Inc., 1832 Asset Management L.P., Two Sigma Investments LP and Standard Life Aberdeen plc. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.
Which major investors are buying Vertex Pharmaceuticals stock?
VRTX stock was acquired by a variety of institutional investors in the last quarter, including Oregon Public Employees Retirement Fund, Jennison Associates LLC, Thrivent Financial for Lutherans, Two Sigma Advisers LP, Geode Capital Management LLC, Assenagon Asset Management S.A., Candriam Luxembourg S.C.A. and Baillie Gifford & Co.. View Insider Buying and Selling for Vertex Pharmaceuticals.
How do I buy shares of Vertex Pharmaceuticals?
Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vertex Pharmaceuticals' stock price today?
One share of VRTX stock can currently be purchased for approximately $186.86.
How big of a company is Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a market capitalization of $47.77 billion and generates $3.05 billion in revenue each year. The pharmaceutical company earns $2.10 billion in net income (profit) each year or $2.83 on an earnings per share basis. Vertex Pharmaceuticals employs 2,500 workers across the globe.
What is Vertex Pharmaceuticals' official website?
How can I contact Vertex Pharmaceuticals?
Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]
MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
